Critical densities and related properties of liquids.

S. Benson

DOI: https://doi.org/10.1021/J150462A016

1948-06-01

Abstract:

What problem does this paper attempt to address?

Secondary sclerosing cholangitis and IgG4-sclerosing cholangitis - A review of cholangiographic and ultrasound imaging

Kathleen Moeller,Barbara Braden,Emma L. Culver,Christian Jenssen,Ehsan Safai Zadeh,Amjad Alhyari,Christian Goerg,Andre Ignee,Michael Hocke,Yi Dong,Siyu Sun,Siegbert Faiss,Christoph F. Dietrich

DOI: https://doi.org/10.4103/EUS-D-22-00208

2023-01-01

Endoscopic Ultrasound

Abstract:Sclerosing cholangitis (SC) represents a spectrum of chronic progressive cholestatic diseases of the intrahepatic and/or extrahepatic biliary system characterized by patchy inflammation, fibrosis, and stricturing. Primary and secondary SC must be distinguished given the different treatment modalities, risks of malignancy, and progression to portal hypertension, cirrhosis, and hepatic failure. This review focuses on secondary SC and the pathogenic mechanisms, risk factors, clinical presentation, and novel imaging modalities that help to distinguish between these conditions. We explore the detailed use of cholangiography and ultrasound imaging techniques.
Primary Sclerosing Cholangitis: Diagnostic Criteria

Nora Cazzagon,Samantha Sarcognato,Elisa Catanzaro,Emanuela Bonaiuto,Matteo Peviani,Francesco Pezzato,Raffaella Motta

DOI: https://doi.org/10.3390/tomography10010005

2024-01-07

Tomography

Abstract:Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by inflammation and fibrosis of intra- and/or extrahepatic bile ducts leading to the formation of multifocal strictures alternated to bile duct dilatations. The diagnosis of the most common subtype of the disease, the large duct PSC, is based on the presence of elevation of cholestatic indices, the association of typical cholangiographic findings assessed by magnetic resonance cholangiography and the exclusion of causes of secondary sclerosing cholangitis. Liver biopsy is not routinely applied for the diagnosis of large duct PSC but is mandatory in the case of suspicion of small duct PSC or overlap with autoimmune hepatitis.

radiology, nuclear medicine & medical imaging
MR Imaging in Primary Sclerosing Cholangitis and Other Cholangitis

Ciara O'Brien,Mikail Malik,Kartik Jhaveri

DOI: https://doi.org/10.1016/j.rcl.2022.05.007

Abstract:Sclerosing cholangitis is characterized by irregular and ill-defined inflammation, fibrosis, and stricturing of the bile ducts and may be primary or secondary in cause. It causes progressive destruction of the biliary tree, progressive parenchymal cirrhosis, hepatic failure, and malignancy such as cholangiocarcinoma. The subtypes of sclerosing cholangitis can be broken down into primary sclerosing cholangitis (PSC), immune-mediated sclerosing cholangitis, infectious cholangitis, and ischemic cholangitis with other causes including metastatic disease and chemotherapy change. MR imaging is the gold standard test to investigate and differentiate PSC and other types of cholangitis.
Cutting edge issues in juvenile sclerosing cholangitis

Angelo Di Giorgio,Diego Vergani,Giorgina Mieli-Vergani

DOI: https://doi.org/10.1016/j.dld.2021.06.028

Abstract:Sclerosing cholangitis (SC) is a rare chronic disorder characterised by inflammation and progressive obliterative fibrosis of the intrahepatic and/or extrahepatic bile ducts. Diagnosis is based on cholangiogram showing bile duct dilatation, narrowing and obliteration of the biliary tree, and histologically, on the presence of inflammatory bile duct damage leading to periductal fibrosis. In children the most common SC is associated with strong autoimmune features, overlapping with those of autoimmune hepatitis (AIH); this form is known as autoimmune sclerosing cholangitis, ASC. Conversely, primary SC (PSC), a condition in which the term "primary" indicates that aetiology and pathogenesis are unknown, is rare in paediatrics. Secondary SC (SSC) defines a cholangiopathy associated with an identifiable aetiology such as immunodeficiencies, infections or haematological disorders. ASC and PSC are strongly associated with inflammatory bowel disease (IBD). ASC responds biochemically well to immunosuppressive drugs and ursodeoxycholic acid (UDCA). Primary forms are exclusively managed with oral UDCA, while in the secondary forms the medical treatment depends on the underlying aetiology. Despite treatment, SC often progresses to biliary cirrhosis and end-stage liver disease requiring liver transplantation. The disease can recur after transplant. Better understanding of pathogenic mechanisms and better treatment modalities are needed to improve the prognosis of this invalidating hepatic disorder.
Secondary sclerosing cholangitis after intensive care unit treatment: clues to the histopathological differential diagnosis

Irene Esposito,Andrea Kubisova,Adolf Stiehl,Hasan Kulaksiz,Peter Schirmacher

DOI: https://doi.org/10.1007/s00428-008-0654-1

Abstract:Secondary sclerosing cholangitis (SSC) is a chronic cholestatic disorder caused by mechanical, infectious, toxic, or ischemic factors. A new variant of SSC occurring after long-term treatment in intensive care units (ICU) has been recently described and characterized from the clinical point of view. The aim of this study was the histomorphological characterization of ICU-treatment-related SSC (ICU-SSC) and the definition of histological changes occurring over time based on the morphological findings. Liver biopsies of ten patients affected by ICU-SSC obtained at different time points (1.5 to 57 months) after the initial injury were analyzed. The main morphological alterations included degenerative changes of portal bile ducts, portal edema, inflammation, and fibrosis as well as biliary interface activity and bilirubinostasis. Perivenular necroses and bile infarcts were found in eight and six patients, respectively. Bile duct loss was not observed. No correlation between morphological features of biopsies and liver chemistry tests or outcome could be established. Based on the morphological observation, a possible disease-progression model starting with an initial damage of portal bile ducts (primary insult) with associated portal/periportal changes (inflammation, ductular reaction) and resulting in secondary parenchymal changes is proposed.
[Primary sclerosing cholangitis-Diagnosis and treatment 2024]

Michael Trauner,Emina Halilbasic,Elisabeth Tatscher,Peter Fickert

DOI: https://doi.org/10.1007/s00108-024-01697-0

Abstract:The etiology of primary sclerosing cholangitis (PSC) remains unclear, which explains in part the lack of a causal treatment. The differential diagnostic distinction from the even rarer immunoglobulin 4 (IgG4)-associated cholangitis (IAC) is becoming increasingly more successful. Advances in the understanding of different clinical courses, improvements in noninvasive diagnostics through modern magnetic resonance imaging (MRI) and the introduction of liver elastography have led to the development of improved prognostic models. The evidence for recommendations on medicinal (e.g., ursodeoxycholic acid) or endoscopic treatment (e.g., balloon dilatation and/or stent insertion) for PSC is still low. In contrast, the long-term results of liver transplantation in PSC patients are constantly improving. Due to the lack of highly sensitive and specific screening methods the early recognition of cholangiocellular carcinoma (CCC) as the most important complication is rarely successful. The continuous improvement of endoscopic retrograde cholangiopancreatography (ERCP) and direct cholangioscopy in combination with molecular biological and fluorescence in situ hybridization (FISH) analyses of bile duct tissue samples are promising for refined diagnostics. Due to the significantly increased risk of colorectal cancer, an annual colonoscopy is recommended in the presence of inflammatory bowel disease. Improvement of the early diagnostics of PSC and successful testing of new treatment strategies raise hope for a continuous improvement in the medical support of these complex patients.
Current Therapeutics in Primary Sclerosing Cholangitis

Natassia Tan,John Lubel,William Kemp,Stuart Roberts,Ammar Majeed

DOI: https://doi.org/10.14218/JCTH.2022.00068S

2023-10-28

Abstract:Primary sclerosing cholangitis (PSC) is an orphan, cholestatic liver disease that is characterized by inflammatory biliary strictures with variable progression to end-stage liver disease. Its pathophysiology is poorly understood. Chronic biliary inflammation is likely driven by immune dysregulation, gut dysbiosis, and environmental exposures resulting in gut-liver crosstalk and bile acid metabolism disturbances. There is no proven medical therapy that alters disease progression in PSC, with the commonly prescribed ursodeoxycholic acid being shown to improve liver biochemistry at low-moderate doses (15-23 mg/kg/day) but not alter transplant-free survival or liver-related outcomes. Liver transplantation is the only option for patients who develop end-stage liver disease or refractory complications of PSC. Immunosuppressive and antifibrotic agents have not proven to be effective, but there is promise for manipulation of the gut microbiome with fecal microbiota transplantation and antibiotics. Bile acid manipulation via alternate synthetic bile acids such as norursodeoxycholic acid, or interaction at a transcriptional level via nuclear receptor agonists and fibrates have shown potential in phase II trials in PSC with several leading to larger phase III trials. In view of the enhanced malignancy risk, statins, and aspirin show potential for reducing the risk of colorectal cancer and cholangiocarcinoma in PSC patients. For patients who develop clinically relevant strictures with cholestatic symptoms and worsening liver function, balloon dilatation is safer compared with biliary stent insertion with equivalent clinical efficacy.
Present and future role of endoscopic retrograde cholangiography in primary sclerosing cholangitis

A Waldthaler,C Schramm,A Bergquist

DOI: https://doi.org/10.1016/j.ejmg.2021.104231

Abstract:Primary sclerosing cholangitis (PSC) is a rare, inflammatory cholestatic liver disease that causes biliary strictures which can lead to secondary complications. About 30-50% of PSC patients develop dominant strictures (DS) in the biliary tree, which are both the cause of jaundice and bacterial cholangitis as well as predilection spots for development of neoplastic development. Cancer is the most common cause of death in PSC. A central concern is to distinguish malignant from benign strictures, which eventually is done by invasive methods to obtain a brush cytology or biopsy sample, in most cases via endoscopic retrograde cholangiography-pancreatography (ERCP). Since medical therapies, like ursodesoxycholic acid or immunosuppressive drugs have no proven effect, therapeutic ERCP has become the primary management strategy to improve symptoms and in some patients may slow down disease progression. This article aims at outlining the current and emerging methods in ERCP in PSC patients.
PRIMARY SCLEROSING CHOLANGITIS IN CHILDREN AND ADOLESCENTS

Eleonora Druve Tavares Fagundes,Alexandre Rodrigues Ferreira,Caroline Caldeira Hosken,Thaís Costa Nascentes Queiroz

DOI: https://doi.org/10.1590/S0004-2803.201700000-50

Abstract:Background: Primary sclerosing cholangitis is a rare disease, but its prevalence has been underestimated in children and adolescents due to broad variation in clinical presentation as well as diagnostic challenges in this life period. Objective: To evaluate children and adolescents with primary sclerosing cholangitis and to describe their clinical, laboratorial, histopathological, and cholangiography conditions. Methods: This is an observational descriptive research that took place from 2005 to 2016 and included all the patients seen in the Outpatient Unit for Pediatric Hepatology of Hospital das Clinicas of UFMG who had been diagnosed with primary sclerosing cholangitis before the age of 18. Diagnosis was established through clinical, laboratory, radiographic and/or histopathologic criteria. Other chronic liver diseases were excluded, as well as secondary causes of cholangitis. Data analysis used statistic resources in SPSS software. Variables were expressed as averages, standard deviation, absolute frequency, and percentage. Results: Twenty-one patients fulfilled criteria to be included in the research sample. Male patients predominated (3.2:1) and average age at diagnosis was 6.7±3.9 years. Five (23.8%) patients had associated inflammatory bowel disease, four had ulcerative colitis and one indeterminate colitis. Signs and symptoms vary and are usually discrete at presentation. The most frequent symptom was abdominal pain (47.6%) followed less frequently by jaundice (28.6%) and itching (14.3%). The reason for medical investigation was asymptomatic or oligosymptomatic enzyme alterations in 33.3% of patients. All patients presented increased hepatic enzymes: aminotransferases, gamma glutamyl transferase, and alkaline phosphatase. Twenty patients had alterations compatible to primary sclerosing cholangitis in their cholangiography exam; one patient had no alterations at magnetic resonance cholangiography, but presented histopathologic alterations that were compatible to small duct cholangitis. Hepatic fibrosis was present in 60% of 15 patients who were biopsied upon admission; cirrhosis being present in four (26.7%) patients. A total of 28.5% of patients had unfavorable outcomes, including two (9.5%) deaths and four (19%) transplants. Conclusion: Primary sclerosing cholangitis is a rare disease in childhood and adolescence and its initial diagnosis may be delayed or overlooked due to asymptomatic or unspecific clinical manifestations. The association with inflammatory bowel disease is common. Prognosis may be unfavorable as the disease progresses and hepatic transplant is the definitive treatment.
Intrahepatic segmental primary sclerosing cholangitis: report of a case

Taku Matsumoto,Tetsuo Ajiki,Ippei Matsumoto,Masahiro Tominaga,Hiroshige Hori,Yoshiyasu Mita,Tsunenori Fujita,Yasuhiro Fujino,Yasuyuki Suzuki,Yonson Ku,Yoshikazu Kuroda

DOI: https://doi.org/10.1007/s00595-006-3218-5

Abstract:A 67-year-old woman was referred to our hospital for investigation of epigastric discomfort. Computed tomography (CT) showed dilatation of the intrahepatic bile duct in the left lobe of the liver, endoscopic cholangiography showed complete stenosis of the left main branch of intrahepatic bile duct, and CT during angiography showed decreased portal blood flow to segment 3 of the liver. Based on these findings, we suspected intrahepatic cholangiocarcinoma and performed left lobectomy of the liver. However, pathological examination revealed fibrosis and infiltration of inflammatory lymphoid cells around the stenotic bile duct and periportal area, without any evidence of malignancy. Since these findings were compatible with sclerosing cholangitis and the patient did not have a disorder that would cause secondary sclerosing cholangitis, the final diagnosis was primary sclerosing cholangitis (PSC). It is difficult to distinguish segmental PSC from cholangiocarcinoma; thus we think surgical resection is an appropriate therapeutic and diagnostic procedure for segmental intrahepatic bile duct stenosis.
Stability of microbial communities in goat milk during a lactation year: molecular approaches.

C. Callon,F. Duthoit,C. Delbès,M. Ferrand,Y. Le Frileux,R. de Crémoux,M. Montel

DOI: https://doi.org/10.1016/J.SYAPM.2007.05.004

IF: 4.064

2007-11-01

Systematic and Applied Microbiology

Abstract:
Carbachol‐induced [Ca2+]i increase, but not activation of protein kinase C, stimulates exocytosis in rat parotid acini

K. Yoshimura,M. Murakami,A. Segawa

DOI: https://doi.org/10.1111/j.1469-7793.2000.t01-1-00403.x

2000-02-01

Journal of Physiology

Abstract:A column perfusion system was applied to rat parotid acinar cells to clarify the roles of Ca2+ and protein kinase C (PKC) in the mechanisms of carbachol (CCh)‐induced amylase secretion. CCh evoked a biphasic response of amylase secretion with an initial rapid and large peak that reached maximum at about 10 s followed by a sustained plateau. The time profile and the dose‐response relationship paralleled with those of cytosolic free Ca2+ concentration ([Ca2+]i). The CCh‐induced sustained response of amylase secretion maintained by Ca2+ influx into cells was ATP dependent, while the initial peak response regulated by Ca2+ released from InsP3‐sensitive stores was relatively ATP independent. Restoration of extracellular Ca2+ during continuous stimulation with CCh in Ca2+‐free medium evoked a second rapid and large peak of amylase secretion. Phorbol 12,13‐dibutyrate (PDBu) potentiated the CCh‐induced amylase secretion in both the initial peak and the sustained plateau without enhancing CCh‐induced [Ca2+]i changes. PKC inhibitors such as Ro 31–8220 inhibited the potentiating effect of PDBu but only slightly reduced amylase secretion induced by CCh alone. These results suggest that a CCh‐induced rise in [Ca2+]i triggers the final fusion and/or exocytosis of amylase secretion. CCh also has some ability to promote ATP‐dependent priming of secretory granules that, together with Ca2+ influxed into cells, contributes to the CCh‐induced sustained plateau of amylase secretion. PDBu‐induced activation of PKC promotes the priming of secretory granules, thereby enhancing the efficacy for Ca2+ to trigger fusion/exocytosis.
Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study.

P. Paquet,S. Jennes,A. Rousseau,F. Libon,P. Delvenne,G. Piérard

DOI: https://doi.org/10.1016/j.burns.2014.01.027

IF: 2.609

2014-12-01

Burns

Abstract:
Phenotypes of Primary Sclerosing Cholangitis and Differential Diagnosis

Brian H Horwich,Douglas T Dieterich

DOI: https://doi.org/10.1016/j.cld.2023.07.006

Abstract:Primary sclerosing cholangitis is a heterogenous immune-mediated disorder characterized by chronic inflammation and stricturing of the bile ducts. Though the driving pathophysiologic mechanisms remain elusive, there are several observed clinical phenotypes of the disease. The distribution of bile duct involvement, presence of concomitant inflammatory bowel disease, significant infiltration of IgG4-positive plasma cells, and overlapping features with other autoimmune disease has significant implications for prognosis and treatment. As there remains no pathognomonic finding for primary sclerosing cholangitis, a broad differential diagnosis and extensive evaluation of other underlying causes is critical to appropriate management.
The Many Faces of Primary Sclerosing Cholangitis: Controversy Abounds

Brian J. Wentworth,Rachita Khot,Stephen H. Caldwell

DOI: https://doi.org/10.1007/s10620-023-08003-2

2023-06-26

Digestive Diseases and Sciences

Abstract:Primary sclerosing cholangitis (PSC) is notoriously challenging to manage given its heterogeneity with regard to diagnosis, management, and progression. The lack of disease-modifying therapy and variable rate of onset of cirrhosis, portal hypertension-related decompensating events, jaundice, pruritus, biliary complications, and need for liver transplantation is deeply unsettling to clinicians and patients alike. Recent updated practice guidance by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver endeavored to highlight some of these challenges. However, these references only briefly address clinical dilemmas that providers face on a daily basis. This review aims to further discuss these controversial topics, including providing insight into the utility of ursodeoxycolic acid, the significance of alkaline phosphatase normalization, when to consider PSC variants and mimickers, and the implications of continuous hepatobiliary malignancy screening. In particular, there has been a growing body of literature raising concern about repeat exposure to gadolinium-containing contrast. Patients with PSC are potentially at risk for large lifetime exposure to gadolinium related to frequent magnetic resonance imaging scans and whether this carries any negative long-term adverse effects remains unknown.

gastroenterology & hepatology
Biliary Cast Syndrome and Secondary Sclerosing Cholangitis in Critically Ill Patient after Long-Term Treatment in the Intensive Care Unit

Adnan Alkurdi,Johannes Herrmann,Damir Bikmukhametov,Rebecca Tschöpe

DOI: https://doi.org/10.1159/000537957

2024-05-10

Abstract:Introduction: Secondary sclerosing cholangitis in critically ill patients (SSC-CIP) is a rare but underdiagnosed entity that occurs after life-threatening events and treatment in the intensive care unit (ICU). The etiology of SSC-CIP is not fully understood but may be caused by ischemic bile duct injury. SSC-CIP is a cholestatic liver disease that rapidly progresses to liver cirrhosis, with a high mortality rate in the first year of 50%. Endoscopic retrograde cholangiopancreatography (ERCP), which is the gold standard for diagnosing SSC-CIP, shows primary SC-like changes, usually in the intrahepatic bile ducts. Biliary cast formation is pathognomonic for SSC-CIP. No proven effective conservative treatment is available for SSC-CIP, and liver transplantation is the only curative therapy when liver cirrhosis or recurrent cholangitis occurs. Case presentation: We report the case of a 47-year-old male patient who developed cholestasis after a long treatment in the ICU for severe pneumonia. ERCP showed characteristic findings with rarefication and multiple segmental stenosis in the intrahepatic bile ducts. We removed multiple biliary casts from the bile ducts. Conclusion: SSC-CIP should be considered for ICU patients with unclear cholestasis, especially when the cholestasis persists after recovery from the underlying disease. Early diagnosis is important to achieve better outcomes; without liver transplantation, the prognosis is generally poor.
Secondary Sclerosing Cholangitis due to Drugs With a Special Emphasis on Checkpoint Inhibitors

Einar S. Bjornsson,Daiana Arnedillo,Fernando Bessone

DOI: https://doi.org/10.1111/liv.16163

IF: 8.754

2024-12-03

Liver International

Abstract:Background Secondary sclerosing cholangitis (SSC), is one of the phenotypes of DILI first described in the 1980s. Check point inhibitors (CPIs) are currently the most frequent cause of SCC. Aims: To describe the epidemiology, clinical and biochemical features at presentation, differential diagnoses, pathophysiology, imaging, histological characteristics and management associated with SSC. Materials and Methods A language and date‐unrestricted Medline literature search was conducted to identify case reports and clinical series on SSC with special emphasis on CPIs (2007‐2023). Results We identified 19 different drugs that have been shown to induce SSC. A total of 64 cases with SSC due to CPIs are presented. This was mostly seen in patients treated with anti‐Programmed cell death (PD)‐1/PD‐L1 inhibitors. The most frequent presenting signs and symptoms were abdominal pain and jaundice. Large‐duct cholangitis induced by CPIs is a very rare condition while small‐duct cholangitis is more common. Nivolumab and pembrolizumab were the most commonly implicated agents. Biopsies have revealed predominant CD8+ T cell infiltration in biliary strictures. Corticosteroids is linked to a low frequency of success and is the only agent recommended to begin the treatment. Conclusions CPIs‐induced SSC seems to affect the entire biliary system. Clinicians should consider and suspect SSC when a probable CPIs‐induced hepatitis does not respond to corticosteroids. Additionally, further randomized, controlled trials should prospectively investigate alternative therapies for treatment.

gastroenterology & hepatology
Primary sclerosing cholangitis and cholangiocarcinoma: the 2023 practice guidance and future perspectives

Francesca Saffioti,Vasileios K. Mavroeidis

DOI: https://doi.org/10.21037/hbsn-23-621

2024-02-01

HepatoBiliary Surgery and Nutrition

Abstract:Primary sclerosing cholangitis and cholangiocarcinoma: the 2023 practice guidance and future perspectives

gastroenterology & hepatology,surgery,nutrition & dietetics
Hedgerow detection in HRS and VHRS images from different source (optical, radar)

D. Ducrot,A. Masse,Abir Ncibi

DOI: https://doi.org/10.1109/IGARSS.2012.6352712

2012-07-22

Abstract:The challenge of recreating a green belt (hedgerow, forest, green corridors ...) is to restore biodiversity that the ecological continuity required. A coherent ecological network allows species to move, interact, and continue to support human being. The main objective of this paper is to explore the potential of image processing methods to map hedgerows, corridors, woodlands of the green belt. We present a methodology based on unsupervised and supervised classification, segmentation and classification fusion. It is applied to a rural landscape and several sensors: Very High and High Resolution, optical and radar satellite, respectively FORMOSAT-2 (8m) SPOT 5 (2.5m and 10m) and TerraSar-X (3m).
AUREOMYCIN-RESISTANT CELL-FREE NITRO REDUCTASE FROM AUREOMYCIN-RESISTANT ESCHERICHIA COLI

A. Saz,L. W. Brownell,R. Slie

DOI: https://doi.org/10.1128/jb.71.4.421-424.1956

IF: 3.2

1956-04-01

Journal of Bacteriology

Abstract:It has previously been reported from this laboratory (Saz and Slie, 1954a) that chlortetracycline ("aureomycin") in concentrations of 1 to 100 ,ug per ml inhibited an enzyme complex from Escherichia coli strain E-26 mediating the reduction of chloramphenicol and other aromatic nitro compounds to the corresponding arylamines. The cofactor requirements for this organic nitro reductase were found to be diphosphopyridine nucleotide (DPN) and i-malic acid (replaceable by reduced DPN), -cysteine and a divalent cation (Saz and Slie, 1954b). In addition, by analogy with non-bacterial systems (Bueding and Jolliffe, 1946; Nason and Evans, 1953; Nicholas and Nason, 1955) a flavin was postulated as an intermediate carrier of electrons between the pyridine nucleotides and the nitro-amino system. In the present paper, the nitro reductase of aureomycm-resistant variants of sensitive E. coli proved resistant to aureomycin both in intact cells and cell-free extracts.

Critical densities and related properties of liquids.

Secondary sclerosing cholangitis and IgG4-sclerosing cholangitis - A review of cholangiographic and ultrasound imaging

Primary Sclerosing Cholangitis: Diagnostic Criteria

MR Imaging in Primary Sclerosing Cholangitis and Other Cholangitis

Cutting edge issues in juvenile sclerosing cholangitis

Secondary sclerosing cholangitis after intensive care unit treatment: clues to the histopathological differential diagnosis

[Primary sclerosing cholangitis-Diagnosis and treatment 2024]

Current Therapeutics in Primary Sclerosing Cholangitis

Present and future role of endoscopic retrograde cholangiography in primary sclerosing cholangitis

PRIMARY SCLEROSING CHOLANGITIS IN CHILDREN AND ADOLESCENTS

Intrahepatic segmental primary sclerosing cholangitis: report of a case

Stability of microbial communities in goat milk during a lactation year: molecular approaches.

Carbachol‐induced [Ca2+]i increase, but not activation of protein kinase C, stimulates exocytosis in rat parotid acini

Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study.

Phenotypes of Primary Sclerosing Cholangitis and Differential Diagnosis

The Many Faces of Primary Sclerosing Cholangitis: Controversy Abounds

Biliary Cast Syndrome and Secondary Sclerosing Cholangitis in Critically Ill Patient after Long-Term Treatment in the Intensive Care Unit

Secondary Sclerosing Cholangitis due to Drugs With a Special Emphasis on Checkpoint Inhibitors

Primary sclerosing cholangitis and cholangiocarcinoma: the 2023 practice guidance and future perspectives

Hedgerow detection in HRS and VHRS images from different source (optical, radar)

AUREOMYCIN-RESISTANT CELL-FREE NITRO REDUCTASE FROM AUREOMYCIN-RESISTANT ESCHERICHIA COLI